skip navigationU S P T O SealUnited States Patent and Trademark Office TTABVUE logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
TTABVUE. Trademark Trial and Appeal Board Inquiry System
v1.9

Summary

Query: Party Name contains all words: NOVARTIS AG
Number of results: 101+
Results are in reverse chronological order

Page #4. Previous 1 2 3 5 Next
Proceeding
Filing Date
Defendant(s),
Property(ies)
Plaintiff(s),
Property(ies)
86932390
08/16/2017
Bausch & Lomb Incorporated
Mark: FORTIFEYE S#:86932390
Novartis AG
91235993
08/07/2017
Novartis AG
Mark: ZIBITRO S#:87222187
Jazz Pharmmaceuticals, Inc.
Mark: XYREM S#:75123252 R#:2249959
Mark: XYREM S#:78769623 R#:3162633
Mark: XYREM S#:78769626 R#:3162634
Mark: XYREM S#:78769629 R#:3162635
Mark: XYREM S#:75577530 R#:2423880
Mark: XYREM S#:75701032 R#:2472156
Mark: XYREM S#:76327130 R#:2860730
Mark: XYREM S#:78769796 R#:3309255
Mark: XYREM S#:78400994 R#:3112732
Mark: XYREM S#:78769619 R#:3162632
Mark: XYREM SUCCESS PROGRAM S#:76397391 R#:2867332
Mark: XYREM PATIENT SUCCESS PROGRAM S#:76412893 R#:2848521
Mark: XYREM SUCCESS PROGRAM FOR PHYSICIANS S#:76412894 R#:2860906
Mark: XYREM (SODIUM OXYBATE) ORAL SOLUTION CIII S#:76427104 R#:2952351
Mark: XYREM S#:78769631 R#:3162636
Mark: XYREM CARECONNECT S#:86643546 R#:5018872
Mark: XYREM CARECONNECT S#:86673318 R#:5078995
86902360
07/26/2017
Glaxo Group Limited
Mark: QYNAETA S#:86902360
Novartis AG
86902351
07/26/2017
Glaxo Group Limited
Mark: QUYNAETA S#:86902351
Novartis AG
87334209
07/14/2017
INTRA-CELLULAR THERAPIES, INC.
Mark: KYPLEETA S#:87334209
Novartis AG
87334207
07/14/2017
INTRA-CELLULAR THERAPIES, INC.
Mark: KIPLYTA S#:87334207
Novartis AG
Novartis AG
86089221
07/14/2017
Azanta A/S
Mark: NIMORAL S#:86089221
Novartis AG
87384621
06/30/2017
Bayer Aktiengesellschaft
Mark: GRANVIO S#:87384621
Novartis AG
87320935
06/20/2017
AbbVie Biotechnology Ltd.
Mark: SKYRIZI S#:87320935
Novartis AG
87276280
06/19/2017
Johnson & Johnson
Mark: RIZEMBRA S#:87276280
Novartis AG
87311918
06/15/2017
Corbus Pharmaceuticals, Inc.
Mark: RESTANVIA S#:87311918
Novartis AG
87232880
06/15/2017
Novartis AG
Mark: TYNFICADE S#:87232880
JANSSEN BIOTECH, INC
87324607
06/13/2017
Dauus Company LLC
Mark: ZORTAX S#:87324607
Novartis AG
91234784
05/30/2017
Leadiant Biosciences Limited
Mark: KYMITA S#:87300964
Novartis AG
Mark: KYNVYTA S#:79186275 R#:5033986
87201770
05/22/2017
Galway Licensing Pty Ltd.
Mark: ACCALIA S#:87201770
Novartis AG
79192250
04/05/2017
FARMACEUTICI DAMOR S.P.A.
Mark: RIGENASE S#:79192250
Novartis AG
87224101
03/30/2017
Impleo Medical, Inc.
Mark: ALUVRA S#:87224101
Novartis AG
87222187
03/09/2017
Novartis AG
Mark: ZIBITRO S#:87222187
JAZZ PHARMACEUTICALS, INC.
87143093
03/07/2017
Celgene Corporation
Mark: ROVIVZEL S#:87143093
Novartis AG
86972596
03/07/2017
Celgene Corporation
Mark: OZMUNE S#:86972596
Novartis AG
87158200
02/21/2017
Glaxo Group Limited
Mark: WISGEMA S#:87158200
Novartis AG
87150030
02/10/2017
Akcea Therapeutics, Inc.
Mark: WAYLIVRA S#:87150030
Novartis AG
86861537
01/16/2017
Recro Pharma, Inc.
Mark: XERIV S#:86861537
Novartis AG
Bristol-Myers Squibb Company
87052637
01/10/2017
Bayer Intellectual Property GmbH
Mark: BREELIB S#:87052637
Novartis AG
86861551
01/04/2017
Recro Pharma, Inc.
Mark: XOLIV S#:86861551
Novartis AG
Page #4. Previous 1 2 3 5 Next

Results as of 11/14/2019 11:43 AMSearch again
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY POLICY